Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Azitra, Inc. - SIC # 2830 -
Ticker
Exchange
SIC #
Website
Latest Ticker
AZTR
NYSE American
2830
azitrainc.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Azitra, Inc.
Azitra, Inc. to Present at the H.C. Wainwright 28th Annual Global Investment Conference
- Sep 8th, 2026 6:00 am
Azitra, Inc. Regains Compliance with NYSE American Continued Listing Standards
- Aug 21st, 2026 6:00 am
Azitra, Inc. Announces Q2 2026 Results and Provides Business Updates
- Aug 12th, 2026 3:00 pm
/C O R R E C T I O N -- Azitra, Inc./
- Jul 15th, 2026 9:33 am
Azitra, Inc. Announces Breakthough Repeat Dose and Anti-Wrinkle Ex Vivo Results for ATR-COSF Program, Demonstrating Increased Distribution and Elasticity
- Jul 15th, 2026 8:10 am
Azitra, Inc. CEO Issues Letter to Shareholders Detailing Strategic Reorientation Initiatives and Outlook for 2026 and Beyond
- Jun 17th, 2026 6:00 am
Azitra, Inc. to Present at 2026 BIO International Convention
- Jun 16th, 2026 3:28 pm
Azitra Announces Adjournment of 2026 Annual Meeting and Information for Reconvened Meeting
- Jun 4th, 2026 2:05 pm
Azitra Announces Intention to Adjourn Annual Meeting and Reconvene Annual Meeting
- May 27th, 2026 2:30 pm
AZTR: More Background on Cosmetic Opportunity
- May 22nd, 2026 5:15 am
Azitra, Inc. Announces Q1 2026 Results and Provides Business Updates
- May 13th, 2026 6:30 am
Azitra, Inc. Announces New U.S. Patent Protecting ATR-12 Program
- May 6th, 2026 6:00 am
Azitra, Inc. Announces Poster Presentation at ASGCT 2026 Highlighting ATR-01 Program for Ichthyosis Vulgaris
- Apr 28th, 2026 6:02 am
Azitra Announces Pricing of Private Placement Financing of up to Approximately $10.5 Million with up to an Additional Approximately $20.9 Million
- Mar 19th, 2026 11:13 am
Azitra Receives Notice of Non-Compliance from NYSE American and Makes NYSE American Section 610(b) Public Announcement
- Mar 13th, 2026 3:15 pm
Azitra, Inc. Announces Cancellation of 2026 Special Meeting of Stockholders
- Mar 5th, 2026 2:30 pm
AZTR: New Site for ATR-04 Trial
- Mar 4th, 2026 1:00 am
Azitra, Inc. Announces Full Year 2025 Results and Provides Business Updates
- Feb 27th, 2026 3:30 pm
Azitra, Inc. Announces Addition of MD Anderson Cancer Center as Clinical Site for Phase 1/2 Trial of ATR-04 Targeting EGFRi-Associated Skin Rash
- Feb 24th, 2026 6:00 am
Azitra, Inc. to Present at BIO Investment & Growth Summit
- Feb 19th, 2026 6:00 am
Scroll